Why did Biogen pay up for Apellis Pharmaceuticals?
Because this may be less about buying a drug and more about buying a nephrology platform.
Our latest argues that kidney disease is starting to look like biotech’s next strategic battleground, and that Biogen’s Apellis deal may be an early signal of where the industry is heading.
Read more: https://biotech.industryexaminer.com/biogen-apellis-kidney-disease-nephrology-biotech/
South Korean biotech firm Alteogen secures exclusive license deal with Biogen for subcutaneous formulation technology, potentially worth up to $549 million in milestones plus royalties, with $20 million upfront payment for developing two biopharmaceutical products using ALT-B4 platform and HybrozymeTM technology.
Biogen triển khai Tofersen tại Trung Quốc, loại thuốc nhắm mục tiêu gen đầu tiên dành cho ALS do đột biến SOD1, đánh dấu đột phá trong điều trị.
Zimmer Biomet ($ZBH) reported EPS of $1.74, matching the forecast of $1.74. Revenue was $1.82B, slightly exceeding the expected $1.8B.
Global Payments ($GPN) achieved EPS of $3.08, just below the forecast of $3.09. Revenue reached $2.6B, surpassing the anticipated $2.38B.
Biogen ($BIIB) posted EPS of $4.08, exceeding the forecast of $3.77. Revenue was $2.47B, slightly above the expected $2.43B.
#Earnings #Q3 #ZimmerBiomet #GlobalPayments #Biogen #Investing #Finance #Stocks #MarketNews
Biogen $BIIB: Q2 EPS of $5.28 beat the forecast of $4.01. Revenue was $2.47B vs. $2.39B expected. #Biogen
Iron Mountain $IRM: Q2 EPS matched the forecast at $0.42. Revenue was $1.53B vs. $1.5B expected. #IronMountain #Earnings #Stocks
Industry Examiner
Yonhap Infomax News
Zougla.gr
Thế Giới Trong Tầm Tay
Tech Cybersecurity Nieuws
ExTraders Global
The Japan Times
EURACTIV Health